References
- Schmidt T, Carmeliet P. Angiogenesis: a target in solid tumors, also in Leukemia? Hematology Am Soc Hematol Educ Program. 2011;2011:1–8.
- Sato T, Goyama S, Kataoka K, et al. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Oncogene. 2014;33:5028–5038.
- Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed Leukemic cells. Cell Stem Cell. 2008;3:207–220.
- Lim IR, Joo HJ, Jeong M, et al. Talin modulation by a synthetic N-Acylurea derivative reduces angiogenesis in human endothelial cells. Int J Mol Sci. 2017;18:e221.
- Martínez-Moreno M, Leiva M, Aguilera-Montilla N, et al. In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins. Leukemia. 2016;30:861–872.
- Bard-Chapeau EA, Jeyakani J, Kok CH, et al. Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proc Natl Acad Sci USA. 2012;109:2168–2173.
- Glass C, Wuertzer C, Cui X, et al. Global identification of EVI1 target genes in acute myeloid leukemia. PLoS One. 2013;8:e67134.
- Kuila N, Nayak KB, Halder A, et al. Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia. Leuk Lymphoma. 2017;58:1941–1947.